2017ARCHRomosozumabIn 4,093 postmenopausal women with high fracture risk, romosozumab followed by alendronate reduced new vertebral, clinical and hip fractures compared with alendronate alone.
2009FREEDOMDenosumabIn 7,868 postmenopausal women with osteoporosis, denosumab 60 mg subcutaneously every 6 months reduced new vertebral, non-vertebral and hip fractures compared with placebo.
2007HORIZON-PFTIntravenous bisphosphonateIn 7,765 postmenopausal women with osteoporosis, annual intravenous zoledronic acid 5 mg reduced new vertebral and hip fractures compared with placebo.
2001Fracture Prevention TrialTeriparatideIn 1,637 postmenopausal women with prior vertebral fractures, teriparatide 20 or 40 µg daily reduced new vertebral and non-vertebral fractures compared with placebo.
1996FIT (Vertebral Fracture Arm)BisphosphonatesIn 2,027 postmenopausal women with ≥1 prevalent vertebral fracture, alendronate reduced new vertebral, clinical and hip fractures compared with placebo.